Aldeyra Stock: Dry Eye Disease Therapy Monetization (NASDAQ:ALDX)
Aldeyra's Reproxalap seems poised for FDA approval for dry eye disease, and it has clear practical advantages. See why I feel ALDX stock is grossly undervalued.
Yoshiyoshi Hirokawa Digitalvision Eye Disease Chamber Crossover Trial Of Reproxalap Eye Disease Crossover Study Aldeyra Therapeutics Inc Perceptive Advisors Eye Disease Aldeyra Therapeutics Inc Aldeyra Therapeutics Inc
Source: seekingalpha.com